MRI imaging and machine learning based radiomics for detection of mixed HCC and CCA tumors: Still a need for liver biopsy? Development and validation of the SPEAR scoring model and predicting overall ...

Shares of Inhibrx Biosciences INBX rallied 36.9% on Wednesday. The massive surge was triggered by encouraging updated interim ...

A randomized, multicenter, open-label, phase 2 study of TRK-950 in combination with ramucirumab and paclitaxel as second-line therapy in patients with Caprin-1 positive gastric or gastroesophageal ...

SAN FRANCISCO -- Three-fourths of patients with unresectable gastroesophageal cancer converted to resectable and had clear margins after treatment with a chemoimmunotherapy combination, a small ...

Results showed treatment with osimertinib reduced the risk of disease progression or death by 84% compared with placebo. The Food and Drug Administration (FDA) has approved Tagrisso ® (osimertinib) ...

The FDA approval of nivolumab plus cisplatin and gemcitabine marks the first concurrent immunotherapy-chemotherapy combination for the population. The trial showed the combination significantly ...

Please provide your email address to receive an email when new articles are posted on . Y-90 resin microspheres are the only approved radioembolization therapy for hepatic cellular carcinoma and ...

Results showed treatment with osimertinib reduced the risk of disease progression or death by 84% compared with placebo. The Food and Drug Administration (FDA) has granted Priority Review to the ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved nivolumab in combination with cisplatin and gemcitabine for the first-line treatment of adults ...

Researchers conducted a multicentre, non-interventional cohort study involving 114 adult patients (58.7% men) with locally advanced, unresectable, stage III NSCLC initiated on durvalumab following ...

The median overall survival was 16.5 months with anlotinib plus penpulimab and 13.2 months with sorafenib. First-line treatment with anlotinib and penpulimab can improve survival outcomes when ...